Conditions: Kidney Neoplasms Carcinoma, Renal Cell
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 62
Healthy volunteers: no

Brief summary:
To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Detailed description:

Arms:
arm 1: AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity

Interventions: intervention 1: AG-013736 (axitinib)
Intervention descriptions: intervention 1: AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.

Protocol document: